Advancement in monoclonal antibody therapy for multiple myeloma

Lancet Haematol. 2020 May;7(5):e354-e355. doi: 10.1016/S2352-3026(20)30098-3. Epub 2020 Mar 23.

Authors

Terri Lynn Shigle¹, Qaiser Bashir²

Affiliations

¹ Division of Pharmacy, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA.
² Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA. Electronic address: QBashir@mdanderson.org.

PMID: 32213343
DOI: 10.1016/S2352-3026(20)30098-3

No abstract available

MeSH terms

ADP-ribosyl Cyclase 1 / antagonists & inhibitors
Administration, Intravenous / adverse effects
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Humans
Infusions, Subcutaneous / adverse effects
Multiple Myeloma / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
daratumumab
ADP-ribosyl Cyclase 1